{"id":"iodixanol-320","safety":{"commonSideEffects":[{"rate":null,"effect":"Contrast-induced nephropathy"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Flushing and warmth sensation"},{"rate":null,"effect":"Arrhythmias"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Iodixanol contains iodine atoms that absorb X-rays, creating contrast between different tissue densities on radiographic images. As an iso-osmolar contrast medium, it has an osmolality equal to blood plasma, which may reduce the risk of contrast-induced nephropathy compared to hyperosmolar agents. It is used intravenously to enhance visualization during angiography, CT, and other radiographic procedures.","oneSentence":"Iodixanol is a non-ionic, iso-osmolar contrast medium that provides radiographic visualization of blood vessels and organs during diagnostic imaging procedures.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:06.751Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Radiographic contrast agent for coronary and peripheral angiography"},{"name":"Contrast agent for computed tomography imaging"},{"name":"Contrast agent for other diagnostic imaging procedures requiring vascular or organ visualization"}]},"trialDetails":[{"nctId":"NCT00804531","phase":"PHASE4","title":"Intra-discal Steroid Injection for MODIC I Discopathy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-04","conditions":"Back Pain Lower Back Chronic","enrollment":137},{"nctId":"NCT00558142","phase":"PHASE4","title":"Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2008-02","conditions":"Radiocontrast-induced Nephropathy","enrollment":107},{"nctId":"NCT05862220","phase":"","title":"Correlation Between Computer Tomography Angiography and D-Dimer Level for the Diagnosis of Pulmonary Embolism","status":"COMPLETED","sponsor":"Zulekha Hospitals","startDate":"2020-12-14","conditions":"D-Dimer as an Early Detector of Pulmonary Embolism","enrollment":28},{"nctId":"NCT03671603","phase":"","title":"Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2018-11-05","conditions":"Coronary Artery Disease, ST-segment Elevation Myocardial Infarction","enrollment":2755},{"nctId":"NCT01136876","phase":"PHASE4","title":"Kidney Damage in Patients With Moderate Fall in eGFR","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2010-11","conditions":"Coronary Artery Stenosis","enrollment":57},{"nctId":"NCT04342455","phase":"NA","title":"A Low-dose Radiation and Contrast Agent Exposure Protocol for Coronary CTA in Diabetic Patients","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2018-10-07","conditions":"Coronary Artery Disease","enrollment":400},{"nctId":"NCT03119662","phase":"PHASE4","title":"A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease","status":"TERMINATED","sponsor":"GE Healthcare","startDate":"2018-02-08","conditions":"Chronic Kidney Diseases","enrollment":4},{"nctId":"NCT00350506","phase":"NA","title":"A Trial Evaluating the Clinical Applicability, Correlation, and Modeling of Cardiac CT Using 64 Detector Row VCT","status":"TERMINATED","sponsor":"GE Healthcare","startDate":"2005-10","conditions":"Coronary Artery Disease","enrollment":77},{"nctId":"NCT00348569","phase":"NA","title":"A Study of Computed Tomography (CT) for Evaluation of Coronary Artery Blockages in Typical or Atypical Chest Pain","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2006-05","conditions":"Coronary Artery Disease","enrollment":245},{"nctId":"NCT00335335","phase":"PHASE3","title":"Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart","status":"TERMINATED","sponsor":"GE Healthcare","startDate":"2006-05","conditions":"Coronary Artery Disease","enrollment":89},{"nctId":"NCT00348608","phase":"PHASE3","title":"Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart","status":"TERMINATED","sponsor":"GE Healthcare","startDate":"2006-06","conditions":"Coronary Artery Disease","enrollment":66},{"nctId":"NCT00793182","phase":"PHASE4","title":"Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography","status":"TERMINATED","sponsor":"Guerbet","startDate":"2009-01","conditions":"Renal Impairment","enrollment":6},{"nctId":"NCT01188486","phase":"NA","title":"Pulmonary Interstitial Lymphography in Early Stage Lung Cancer","status":"TERMINATED","sponsor":"Stanford University","startDate":"2010-08","conditions":"Lung Cancer, Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer Small Cell Lung Cancer (SCLC)","enrollment":12},{"nctId":"NCT01534975","phase":"NA","title":"Comparison of Contrast Agents During CT Angiography","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2012-01","conditions":"Contrast Enhancement on Cardiac CT","enrollment":513},{"nctId":"NCT03333330","phase":"PHASE3","title":"IMaging Della PLAcca Carotidea","status":"COMPLETED","sponsor":"Enrico Ammirati","startDate":"2012-04","conditions":"Carotid Artery Plaque, Atherosclerosis, Ischemic Stroke","enrollment":75},{"nctId":"NCT02476526","phase":"PHASE4","title":"Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease","status":"COMPLETED","sponsor":"VA Greater Los Angeles Healthcare System","startDate":"2008-09","conditions":"Chronic Kidney Disease, Pulmonary Embolism, Renal Artery Stenosis","enrollment":50},{"nctId":"NCT01935141","phase":"NA","title":"Efficacy of Low (30ml) Versus Full Dose (100ml) Contrast CT Pulmonary Angiography in Detecting Emboli","status":"WITHDRAWN","sponsor":"VA Greater Los Angeles Healthcare System","startDate":"2016-01","conditions":"Multiple Pulmonary Emboli","enrollment":""},{"nctId":"NCT02718521","phase":"NA","title":"Adequate Hydration Therapy Combined With Intravenous Infusion of Isosorbide Dinitrate Prevention for CIN","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2016-03","conditions":"Cardio-Renal Syndrome","enrollment":400},{"nctId":"NCT01908309","phase":"EARLY_PHASE1","title":"Contrast-inDuced nephRotoxicity as Assessed by the KIdney Load-to-DAmage RElationship","status":"COMPLETED","sponsor":"Azienda Sanitaria Locale 9, Grosseto","startDate":"2013-04","conditions":"Contrast Induced Acute Kidney Injury","enrollment":150},{"nctId":"NCT02405377","phase":"NA","title":"Central Venous Pressure Guided Hydration Prevention for Contrast-Induced Nephropathy","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2014-02","conditions":"Cardio-Renal Syndrome","enrollment":264},{"nctId":"NCT00209417","phase":"PHASE4","title":"Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography","status":"TERMINATED","sponsor":"GE Healthcare","startDate":"2005-06","conditions":"Renal Insufficiency, Diabetes Mellitus","enrollment":656},{"nctId":"NCT01549379","phase":"NA","title":"Dynamic Contrast Enhanced Computed Tomography (CT) for Head and Neck Cancer","status":"TERMINATED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2013-07","conditions":"Head and Neck Cancer","enrollment":1},{"nctId":"NCT02171247","phase":"PHASE3","title":"Comparison of Isovue 370 vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA)","status":"COMPLETED","sponsor":"Duke University","startDate":"2008-04","conditions":"Coronary Computed Tomographic Angiography","enrollment":35},{"nctId":"NCT01475097","phase":"PHASE4","title":"Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2011-10","conditions":"Drug Safety","enrollment":255},{"nctId":"NCT01136915","phase":"PHASE4","title":"Kidney Damage In Patients With Severe Fall In eGFR","status":"TERMINATED","sponsor":"Bracco Diagnostics, Inc","startDate":"2010-11","conditions":"Coronary Artery Stenosis","enrollment":15},{"nctId":"NCT01376089","phase":"PHASE4","title":"Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2011-05","conditions":"Patient Comfort and Safety","enrollment":304},{"nctId":"NCT01137786","phase":"PHASE4","title":"Kidney Damage in Patients With Normal eGFR","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2010-12","conditions":"Coronary Artery Stenosis","enrollment":49},{"nctId":"NCT01402219","phase":"PHASE4","title":"Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients","status":"TERMINATED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2008-11","conditions":"Chronic Renal Disease","enrollment":204},{"nctId":"NCT01004770","phase":"PHASE1, PHASE2","title":"Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT)","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2009-10","conditions":"Healthy","enrollment":50},{"nctId":"NCT00782639","phase":"PHASE4","title":"Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients","status":"TERMINATED","sponsor":"Bracco Diagnostics, Inc","startDate":"2009-03","conditions":"Chronic Renal Impairment, Diabetes Mellitus","enrollment":23},{"nctId":"NCT00926562","phase":"PHASE4","title":"A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2009-02","conditions":"Kidney Failure, Chronic","enrollment":592},{"nctId":"NCT00390585","phase":"PHASE4","title":"Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST)","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2006-07","conditions":"Renal Insufficiency, Chronic, Angioplasty, Transluminal, Percutaneous Coronary, Coronary Arteriosclerosis","enrollment":324},{"nctId":"NCT00479024","phase":"","title":"Follow-up Study to Previous CARE Trial","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2007-06","conditions":"Moderate to Severe Chronic Kidney Disease","enrollment":294},{"nctId":"NCT00351754","phase":"PHASE4","title":"Detection of Pulmonary Embolism With CECT","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2006-07","conditions":"Pulmonary Embolism","enrollment":120},{"nctId":"NCT00209430","phase":"PHASE4","title":"Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2005-08","conditions":"Coronary Artery Disease, Renal Impairment","enrollment":408},{"nctId":"NCT00209404","phase":"PHASE4","title":"Iodixanol in Multidetector-Row Computed Tomography-Coronary Angiography (MDCT-CA)","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2005-07","conditions":"Coronary Artery Disease","enrollment":50}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"CONTRAST MEDIA REACTION"},{"count":5,"reaction":"RENAL FAILURE ACUTE"},{"count":4,"reaction":"BLOOD CREATININE INCREASED"},{"count":3,"reaction":"NEPHROPATHY TOXIC"},{"count":3,"reaction":"PYREXIA"},{"count":2,"reaction":"DYSPNOEA"},{"count":2,"reaction":"HYPOTENSION"},{"count":2,"reaction":"VOMITING"},{"count":1,"reaction":"ACUTE MYOCARDIAL INFARCTION"},{"count":1,"reaction":"ACUTE PRERENAL FAILURE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["VISIPAQUE (TM)"],"phase":"marketed","status":"active","brandName":"Iodixanol 320","genericName":"Iodixanol 320","companyName":"Bracco Diagnostics, Inc","companyId":"bracco-diagnostics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iodixanol is a non-ionic, iso-osmolar contrast medium that provides radiographic visualization of blood vessels and organs during diagnostic imaging procedures. Used for Radiographic contrast agent for coronary and peripheral angiography, Contrast agent for computed tomography imaging, Contrast agent for other diagnostic imaging procedures requiring vascular or organ visualization.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}